MorphoSys Trial for Blood-Cancer Treatment Reaches Primary Endpoint
20 Novembre 2023 - 11:19PM
Dow Jones News
By Ben Glickman
MorphoSys said its study of a treatment for myelofibrosis, a
rare form of blood cancer, reached its primary endpoint, clearing
the way for a new drug application in mid-2024.
The German pharmaceutical company said Monday its Phase 3 trial
of pelabresib in combination with ruxolitinib in myelofibrosis
patients found a statistically significant and clinically
meaningful improvement in the portion of patients with a 35% or
greater reduction in spleen volume after 24 weeks.
There was also a meaningful reduction in myelofibrosis symptoms,
a key secondary endpoint, according to the company.
MorphoSys now intends to submit a new drug application for
pelabresib in combination with ruxolitinib to U.S. and European
regulators in mid-2024.
The company's combination therapy received fast track
designation from the Food and Drug Administration in treating
myelofibrosis in 2018.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
November 20, 2023 17:04 ET (22:04 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
MorphoSys (NASDAQ:MOR)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
MorphoSys (NASDAQ:MOR)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
